Obstetrics & Gynaecology

Top Medical News
Betamethasone falls short of reducing neonatal respiratory complications
3 days ago
Administering betamethasone in the late preterm period to pregnant women at risk of delivering prematurely does not appear to reduce the risk of neonatal respiratory distress, according to a study.
Breastfeeding delivers long-term cardiometabolic benefits in offspring
Audrey Abella, 3 days ago
In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.
Quitting smoking in pregnancy tied to weight gain and high HDP risk, but lower stillbirth risk
4 days ago
Smoking discontinuation during pregnancy is associated with both positive and negative outcomes, such as reduced risk of stillbirth but higher risk of hypertensive disorders of pregnancy (HDP) and weight gain, according to a study.
Apixaban recommended for blood clot prevention in gynaecologic cancer surgery
5 days ago
Prophylactic apixaban appears to effectively reduce the risk of venous thromboembolism (VTE) for patients undergoing open surgery for gynaecologic malignancies and should be considered the standard of care for VTE prophylaxis in this population, according to a retrospective study.
Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates
Audrey Abella, 23 Feb 2024
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.
Higher aspirin dose may attenuate severe pre-eclampsia risk among high-risk women with obesity
Jairia Dela Cruz, 20 Feb 2024
Doubling the routine aspirin dose used for pre-eclampsia prevention appears to help lower the risk of developing pre-eclampsia with severe features among high-risk pregnant women with obesity, according to the results of the open-label ASPREO trial.
Metformin offers no benefit for pre-eclampsia in pregnant women with diabetes
Jairia Dela Cruz, 19 Feb 2024
Adding metformin to insulin neither lowers the risk of developing preterm pre-eclampsia nor improves the risk markers of cardiovascular disease in pregnant women who have received a diagnosis of diabetes early in pregnancy or have existing type 2 diabetes mellitus, according to a study.
Special Reports
Management of recurrent implantation failure during the COVID-19 pandemic
Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC
15 Nov 2021
Adding ribociclib (KISQALI, Novartis) to letrozole yields significant and consistent overall survival (OS) benefit compared with letrozole alone in the first-line setting for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), according to the final OS analysis of the MONALEESA-2 trial presented at ESMO 2021.
The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib
Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Atezolizumab + chemo gets greenlight from HSA for PD-L1+ TNBC
Pearl Toh, 15 Aug 2020
Atezolizumab, in combination with the chemotherapy nab-paclitaxel, has been approved by the Singapore Health Sciences Authority (HSA) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive (PD-L1+) triple-negative breast cancer (TNBC) — adding to the growing market list this drug has been granted approval for TNBC.
Antioxidant and micronutrient supplementation on the sperm parameters of male patients with idiopathic infertility: An update
09 Jun 2020
Infertility is a problem faced by 5-10 percent of couples, with male factor accounting for up to 47 percent of cases. [Int J Androl 1987;7(Suppl):1]. There are many causes for male infertility but up to 15 percent of cases are idiopathic in nature. These cases may be related to unregulated excessive oxidative stress, which may impair spermatogenesis; hence, arousing research into the role of antioxidant supplementation in improving the sperm parameters.
Expert consensus: Patient profile should
guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
The safe and rational use of ulipristal for fibroids
Dr. Siow Yew Ming Anthony, 20 Jun 2019
Fibroids or leiomyomas are the most common benign smooth muscle tumours of the uterus. They are often detected at screening ultrasound in asymptomatic patients. A fibroid will naturally grow until menopause and subsequently shrink when female hormone levels drop.
Conference Reports
Breastfeeding delivers long-term cardiometabolic benefits in offspring
Audrey Abella, 27 Feb 2024
In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.
Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates
Audrey Abella, 23 Feb 2024
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.
Higher aspirin dose may attenuate severe pre-eclampsia risk among high-risk women with obesity
Jairia Dela Cruz, 20 Feb 2024
Doubling the routine aspirin dose used for pre-eclampsia prevention appears to help lower the risk of developing pre-eclampsia with severe features among high-risk pregnant women with obesity, according to the results of the open-label ASPREO trial.
Metformin offers no benefit for pre-eclampsia in pregnant women with diabetes
Jairia Dela Cruz, 19 Feb 2024
Adding metformin to insulin neither lowers the risk of developing preterm pre-eclampsia nor improves the risk markers of cardiovascular disease in pregnant women who have received a diagnosis of diabetes early in pregnancy or have existing type 2 diabetes mellitus, according to a study.
Revised obstetric VTE prophylaxis protocol prevents wound hematomas
Stephen Padilla, 16 Feb 2024
Adopting a more conservative approach to venous thromboembolism (VTE) prophylaxis results in reduced rates of wound hematomas, with no increase in postpartum VTE, according to a recent study presented at SMFM 2024.
High oxytocin dose helps reduce postpartum haemorrhage
Stephen Padilla, 15 Feb 2024
Use of high-dose oxytocin postpartum appears to result in reduced rates of postpartum haemorrhage (PPH) when compared with traditional doses, as shown in a study presented at SMFM 2024.
Dr Shusen Wang, ESMO Asia 2023
Elaine Soliven, 12 Jan 2024

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.